Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $86.86 Consensus Target Price from Analysts

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $86.8571.

A number of research firms recently weighed in on ESTA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. Wall Street Zen downgraded shares of Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Stephens raised their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Needham & Company LLC raised their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $88.00 target price on shares of Establishment Labs in a research report on Wednesday.

Establishment Labs Stock Up 9.9%

Establishment Labs stock opened at $68.63 on Friday. The company has a market cap of $2.02 billion, a P/E ratio of -39.44 and a beta of 1.08. Establishment Labs has a 1-year low of $30.50 and a 1-year high of $83.31. The company has a fifty day simple moving average of $65.53 and a 200 day simple moving average of $65.71. The company has a current ratio of 3.04, a quick ratio of 2.00 and a debt-to-equity ratio of 10.51.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The business had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The firm’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.19) earnings per share. Research analysts anticipate that Establishment Labs will post -0.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Quiros Juan Jose Chacon sold 42,642 shares of the firm’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $65.43, for a total value of $2,790,066.06. Following the completion of the transaction, the director owned 1,139,862 shares of the company’s stock, valued at approximately $74,581,170.66. This trade represents a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 150,000 shares of company stock valued at $9,629,263 over the last ninety days. 9.99% of the stock is currently owned by company insiders.

Institutional Trading of Establishment Labs

A number of large investors have recently added to or reduced their stakes in ESTA. Quarry LP acquired a new stake in Establishment Labs in the third quarter valued at $34,000. Kestra Advisory Services LLC acquired a new stake in Establishment Labs in the fourth quarter valued at $47,000. State of Wyoming acquired a new stake in Establishment Labs in the third quarter valued at $71,000. Osaic Holdings Inc. lifted its stake in Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after acquiring an additional 1,800 shares during the last quarter. Finally, MV Capital Management Inc. acquired a new stake in Establishment Labs in the fourth quarter valued at $146,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.